By Colin Kellaher


Shares of Global Blood Therapeutics Inc. edged higher in premarket trading Monday after the biopharmaceutical company agreed to be acquired by Pfizer Inc. in a transaction valued at about $5.4 billion, including assumed debt.

New York-based Pfizer said it would pay $68.50 a share in cash for Global Blood, a 7.3% premium to Friday's closing price of $63.84 but more than double its closing price of $33.93 on Aug. 3, before published reports emerged that potential buyers were circling the South San Francisco, Calif., company.

Global Blood shares, which ended Friday's session with a gain of 33%, were recently changing hands at $66.36, up 4%.


Write to Colin Kellaher at


(END) Dow Jones Newswires

August 08, 2022 07:14 ET (11:14 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 8 2022 まで 9 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 9 2021 まで 9 2022 Pfizerのチャートをもっと見るにはこちらをクリック